This profile was last updated on //
Is this you? Claim your profile.
Broughton House 31 Dunedin Street
Dunedin Street Edinburgh,
Myeloma UK was founded in 1997. Our mission underpins all of our strategic objectives, programmes and services. Furthermore, those who work on behalf of Myeloma UK understand and embrace our mission.
Find other employees at this company (76)
(61 Total References)
Board of Directors | Myeloma UK
www.myeloma.org.uk, 28 Nov 2015 [cached]
Prof Atul Mehta
www.myeloma.org.uk, 29 Nov 2010 [cached]
Dr Atul Mehta
Royal Free Hospital, London
www.cbsaworld.org, 18 Nov 2015 [cached]
Prof. Atul Mehta
Prof. Atul Mehta was born in Kenya of Asian parents and came to London at a young age.
trained in medicine at Cambridge University
and King's College Hospital
, London, qualifying in 1978.
postgraduate training in haematology was largely in London's Hammersmith Hospital
was appointed to his
present post as Consultant Haematologist at the Royal Free Hospital
He was appointed Professor of the University College London in August 2010.
became interested in myeloma in 1987 when asked to develop services for myeloma patients at the Royal Free
The department had a very large Clinical Bone Marrow Transplant Service and he
collaborated with Prof Tim McElwain and his
colleagues at The Royal Marsden to pilot treatment strategies using C-VAMP and high-dose melphalan with autologous bone marrow transplant.
He is also the Clinical Director of the Lysosomal Storage Disorders Unit at the Royal Free.
Cell Therapeutics Investor Relations
www.corporate-ir.net, 30 July 2003 [cached]
In the UK, Dr Atul Mehta, Consultant Hematologist at the Royal Free Hospital, London has already started to treat one of his patients with TRISENOX."I have recently started my first patient on TRISENOX following her relapse whilst on a chemotherapy regimen," he commented.
Dr Atul Mehta, haematologist ...
www.myelomaonline.org.uk, 28 Sept 2008 [cached]
Dr Atul Mehta, haematologist consultant at the Royal Free Hospital, London, commented: "These survey findings reveal the dismal state of UK cancer management.